Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

Werewolf Therapeutics and Ambros Therapeutics Announce

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first

Why Werewolf Therapeutics stock exploded higher and what comes next?

Werewolf Therapeutics (HOWL) stock exploded higher on Friday morning after management said the company has agreed to a definitive all-stock merger with Ambros Therapeutics. The combined company will pivot to focus on Ambros' Phase 3 drug candidate – neridronate – for Complex Regional Pain Syndrome Type 1 (CRPS-1), backed by an oversubscribed $150 million private placement from top-tier institutional investors like RA Capital and Janus Henderson.…

Cooley Advised Ambros Therapeutics on $550 Million Merger With Werewolf Therapeutics, Concurrent $150 Million Private Financing // Cooley // Global Law Firm

Werewolf merger deal at $47.5 million is double its market cap, leaves holders down 6.8%

WALTHAM, Massachusetts, August 21, 2026, 09:22 EDT — U.S. stocks traded in premarket hours. Werewolf’s agreed value stands at $47.5 million, compared with its market capitalization of $21.0 million.Current shareholders receive approximately 6.8% of the merged entity, in addition to rights linked to legacy assets.The neridronate program is anticipated to be funded through the first…

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent ...